â– LECTURE OVERVIEW: Polycystic Ovary Syndrome (PCOS, Stein-Leventhal syndrome) is a metabolic-endocrine disorder and a leading cause of female infertility.
â– ENDOCRINE PATHWAY DETAIL:
1. Hyperinsulinemia: The primary driver is marked insulin resistance. Hyperinsulinemia suppresses hepatic synthesis of Sex Hormone-Binding Globulin (SHBG).
2. Free Testosterone Surge: Lower SHBG increases circulating free testosterone, driving clinical hyperandrogenism.
3. LH Excess: Pulsatile GnRH release favors the synthesis of Luteinizing Hormone (LH) over Follicle-Stimulating Hormone (FSH), elevating the LH:FSH ratio above 2.
4. Androgen Production: Excess LH stimulates ovarian Theca cells to produce androstenedione. Decreased relative FSH impairs granulosa cell aromatase activity, preventing conversion to estrogens.
5. Anovulation: Follicle maturation halts midway, presenting on ultrasound as multiple subcortical cysts (the 'string of pearls' appearance).
â– TOXICOLOGICAL OVERDOSAGE PROTOCOL:
Toxic absorption or cumulative exposure results in receptor saturation, chemical cell damage, or severe secondary target-organ failure. Immediate toxicological profiles dictate serum or urine screens.
â– MOLECULAR PATHWAY DYNAMICS:
Intracellular cascades undergo profound modifications, altering secondary transcription levels and receptor presentation on cellular membranes.
[HY-BOARD-1079]
🌟 Dynamic Clinical Key:
PCOS is diagnosed using the Rotterdam criteria, requiring 2 of 3 features: clinical/biochemical hyperandrogenism (hirsutism, acne), ovulatory dysfunction (oligomenorrhea), or polycystic ovaries on ultrasound. It is associated with a high risk of endometrial hyperplasia and cancer due to unopposed estrogen. Administer physiological antidotes and active elimination therapies (activated charcoal or hemodialysis) without delay. Therapeutic molecules targeting upstream signaling components demonstrate superior efficacy profiles.